留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

反义寡核苷酸的作用机制及其在运动系统中的研究进展

杨建乐 吴南

杨建乐, 吴南. 反义寡核苷酸的作用机制及其在运动系统中的研究进展[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2023-0656
引用本文: 杨建乐, 吴南. 反义寡核苷酸的作用机制及其在运动系统中的研究进展[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2023-0656
YANG Jianle, WU Nan. Mechanism of Action of Antisense Oligonucleotides and Their Research Progress in the Musculoskeletal System[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2023-0656
Citation: YANG Jianle, WU Nan. Mechanism of Action of Antisense Oligonucleotides and Their Research Progress in the Musculoskeletal System[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2023-0656

反义寡核苷酸的作用机制及其在运动系统中的研究进展

doi: 10.12290/xhyxzz.2023-0656
基金项目: 

中国医学科学院医学与健康科技创新工程(2021-I2M-1-051); 北京协和医院中央高水平医院临床科研专项(2022-PUMCH-C-033)

详细信息
    通讯作者:

    吴南,E-mail:dr.wunan@pumch.cn

  • 中图分类号: R681; R746

Mechanism of Action of Antisense Oligonucleotides and Their Research Progress in the Musculoskeletal System

Funds: 

CAMS Innovation Fund for Medical Sciences (2021-I2M-1-051); National High Level Hospital Clinical Research Funding (2022-PUMCH-C-033)

  • 摘要: 反义寡核苷酸(antisense oligonucleotides,ASOs)是一类新型的小分子基因靶向药物,可与目的mRNA结合,ASOs以其与目标序列互补的碱基配对方式,对基因进行靶向调控。随着基因测序技术和分子合成技术的不断发展,ASOs在运动系统中的研究和应用进一步深入。本文阐述了ASOs在基因沉默和表达调控中的作用机制,以及其在基因治疗方面的应用前景。此外,还介绍了ASOs在运动系统疾病中的研究进展和应用情况,并分析此类药物目前所面临的亟待解决的问题,旨在深化医务人员对ASOs的认识,并为其在生物医学研究和临床中的推广应用提供有益参考。
  • [1] J A Doudna, E Charpentier. Genome editing. The new frontier of genome engineering with CRISPR-Cas9[J]. Science, 2014, 346(6213): 1258096.
    [2] C Happi Mbakam, G Lamothe, G Tremblay, et al. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy[J]. Neurotherapeutics, 2022, 19(3): 931-41.
    [3] K I Fujita, T Ishizuka, M Mitsukawa, et al. Regulating Divergent Transcriptomes through mRNA Splicing and Its Modulation Using Various Small Compounds[J]. Int J Mol Sci, 2020, 21(6).
    [4] X Li, W Pu, Q Zheng, et al. Proteolysis-targeting chimeras (PROTACs) in cancer therapy[J]. Mol Cancer, 2022, 21(1): 99.
    [5] A Goga, M Stoffel. Therapeutic RNA-silencing oligonucleotides in metabolic diseases[J]. Nat Rev Drug Discov, 2022, 21(6): 417-39.
    [6] S T Crooke, B F Baker, R M Crooke, et al. Antisense technology: an overview and prospectus[J]. Nat Rev Drug Discov, 2021, 20(6): 427-53.
    [7] C F Bennett. Therapeutic Antisense Oligonucleotides Are Coming of Age[J]. Annu Rev Med, 2019, 70: 307-21.
    [8] R S Finkel, E Mercuri, B T Darras, et al. Nusinersen versus Sham Control in InfantileOnset Spinal Muscular Atrophy[J]. N Engl J Med, 2017, 377(18): 1723-32.
    [9] M D de Smet, C J Meenken, G J van den Horn. Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis[J]. Ocul Immunol Inflamm, 1999, 7(3-4): 189-98.
    [10] NCT03647228. A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONISENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis[Z]. 2021
    [11] X H Liang, H Sun, J G Nichols, et al. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus[J]. Mol Ther, 2017, 25(9): 2075-92.
    [12] S T Crooke. Molecular Mechanisms of Antisense Oligonucleotides[J]. Nucleic Acid Ther, 2017, 27(2): 70-7.
    [13] I R Reid, E O Billington. Drug therapy for osteoporosis in older adults[J]. Lancet, 2022, 399(10329): 1080-92.
    [14] E Canalis, T R Grossman, M Carrer, et al. Antisense oligonucleotides targeting Notch2 ameliorate the osteopenic phenotype in a mouse model of Hajdu-Cheney syndrome[J]. J Biol Chem, 2020, 295(12): 3952-64.
    [15] L Sharma. Osteoarthritis of the Knee[J]. N Engl J Med, 2021, 384(1): 51-9.
    [16] A Nakamura, Y R Rampersaud, S Nakamura, et al. microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints[J]. Ann Rheum Dis, 2019, 78(1): 111-21.
    [17] R Tamura. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis[J]. Int J Mol Sci, 2021, 22(11).
    [18] A Leier, M Moore, H Liu, et al. Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I[J]. Mol Ther Nucleic Acids, 2022, 28: 261-78.
    [19] A Aartsma-Rus, I B Ginjaar, K Bushby. The importance of genetic diagnosis for Duchenne muscular dystrophy[J]. J Med Genet, 2016, 53(3): 145-51.
    [20] I E C Verhaart, A Aartsma-Rus. Therapeutic developments for Duchenne muscular dystrophy[J]. Nat Rev Neurol, 2019, 15(7): 373-86.
    [21] G Patterson, H Conner, M Groneman, et al. Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach[J]. Eur J Pharmacol, 2023, 947: 175675.
    [22] S Cirak, V Arechavala-Gomeza, M Guglieri, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study[J]. Lancet, 2011, 378(9791): 595-605.
    [23] D E Frank, F J Schnell, C Akana, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy[J]. Neurology, 2020, 94(21): e2270-e82.
    [24] E Mercuri, C J Sumner, F Muntoni, et al. Spinal muscular atrophy[J]. Nat Rev Dis Primers, 2022, 8(1): 52.
    [25] T Fang, G Je, P Pacut, et al. Gene Therapy in Amyotrophic Lateral Sclerosis[J]. Cells, 2022, 11(13).
    [26] T M Miller, M E Cudkowicz, A Genge, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS[J]. N Engl J Med, 2022, 387(12): 1099-110.
    [27] X Chi, P Gatti, T Papoian. Safety of antisense oligonucleotide and siRNA-based therapeutics[J]. Drug Discov Today, 2017, 22(5): 823-33.
    [28] T Ramasamy, H B Ruttala, S Munusamy, et al. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics[J]. J Control Release, 2022, 352: 861-78.
    [29] A J Debacker, J Voutila, M Catley, et al. Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug[J]. Mol Ther, 2020, 28(8): 1759-71.
    [30] T C Roberts, R Langer, M J A Wood. Advances in oligonucleotide drug delivery[J]. Nat Rev Drug Discov, 2020, 19(10): 673-94.
  • 加载中
计量
  • 文章访问数:  30
  • HTML全文浏览量:  3
  • PDF下载量:  3
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-12-27
  • 录用日期:  2024-01-15
  • 网络出版日期:  2024-03-05

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!